The Enterprise Value as of November 2024 (TTM) for MoonLake Immunotherapeutics (MLTX) is 3.05B

According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current Enterprise Value is 3.05B. This represents a change of 12.60% compared to the average of 2.71B of the last 4 quarters.

MoonLake Immunotherapeutics (MLTX) Historical Enterprise Value (quarterly & annually)

How has MLTX Enterprise Value performed in the past?

The mean historical Enterprise Value of MoonLake Immunotherapeutics over the last ten years is 759.92M. The current 3.05B Enterprise Value has changed 40.08% with respect to the historical average. Over the past ten years (40 quarters), MLTX's Enterprise Value was at its highest in in the December 2023 quarter at 3.17B. The Enterprise Value was at its lowest in in the December 2020 quarter at 0.

MoonLake Immunotherapeutics (MLTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of MoonLake Immunotherapeutics Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MoonLake Immunotherapeutics (MLTX) Average Enterprise Value

How has MLTX Enterprise Value performed in the past?

The current Enterprise Value of MoonLake Immunotherapeutics (MLTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

MoonLake Immunotherapeutics (MLTX) Enterprise Value vs. Peers

How is MLTX’s Enterprise Value compared to its peers?

MoonLake Immunotherapeutics’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (0), greater than Day One Biopharmaceuticals, Inc. (222.97M), greater than Acumen Pharmaceuticals, Inc. (963.46M), greater than Amylyx Pharmaceuticals, Inc. (139.19M), greater than Aerovate Therapeutics, Inc. (291.98M), greater than Enliven Therapeutics, Inc. (46.23M), greater than Structure Therapeutics Inc. (1.10B), greater than Compass Therapeutics, Inc. (1.75B), greater than Ventyx Biosciences, Inc. (182.75M), greater than Nuvalent, Inc. (80.09M), less than Cerevel Therapeutics Holdings, Inc. (6.38B), less than Travere Therapeutics, Inc. (8.24B), greater than Arcellx, Inc. (1.95B), less than Akero Therapeutics, Inc. (4.79B), greater than 89bio, Inc. (2.00B), greater than Pliant Therapeutics, Inc. (940.63M), greater than null (770.48M),

Build a custom stock screener for MoonLake Immunotherapeutics (MLTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MoonLake Immunotherapeutics (MLTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.